Related references
Note: Only part of the references are listed.Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values
Gabor Cserni et al.
BREAST (2014)
A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue
Arvydas Laurinavicius et al.
BREAST CANCER RESEARCH (2014)
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
S. Ohno et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study
Yoshiki Mikami et al.
CANCER SCIENCE (2013)
Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Gunter von Minckwitz et al.
CLINICAL CANCER RESEARCH (2013)
An International Ki67 Reproducibility Study
Mei-Yin C. Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
An Intra- and Interobserver Reproducibility Analysis of the Ki-67 Proliferation Marker Assessment on Core Biopsies of Breast Cancer Patients and Its Potential Clinical Implications
Andras Voeroes et al.
PATHOBIOLOGY (2013)
Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer
Naoki Niikura et al.
CANCER SCIENCE (2012)
Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer
Einar Gudlaugsson et al.
HISTOPATHOLOGY (2012)
How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists
Zsuzsanna Varga et al.
PLOS ONE (2012)
Is the Ki-67 labelling index ready for clinical use?
W. Jonat et al.
ANNALS OF ONCOLOGY (2011)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Jack Cuzick et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
R. Stuart-Harris et al.
BREAST (2008)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
Share Paper
